These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. Investigation of synergism of meropenem and ciprofloxacin against Pseudomonas aeruginosa and Acinetobacter strains isolated from intensive care unit infections. Ermertcan S, Hoşgör M, Tünger O, Coşar G. Scand J Infect Dis; 2001 Jul; 33(11):818-21. PubMed ID: 11760161 [Abstract] [Full Text] [Related]
15. Italian survey on comparative levofloxacin susceptibility in 334 clinical isolates of Pseudomonas aeruginosa. Segatore B, Setacci D, Perilli M, Franceschini N, De Santis A, Marchetti F, Amicosante G. Antimicrob Agents Chemother; 1999 Feb; 43(2):428-31. PubMed ID: 9925553 [Abstract] [Full Text] [Related]
16. Comparison of antibacterial activities of meropenem and six other antimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials. Iaconis JP, Pitkin DH, Sheikh W, Nadler HL. Clin Infect Dis; 1997 Feb; 24 Suppl 2():S191-6. PubMed ID: 9126693 [Abstract] [Full Text] [Related]
17. In vitro activity of trovafloxacin in combination with ceftazidime, meropenem, and amikacin. Milatovic D, Wallrauch C. Eur J Clin Microbiol Infect Dis; 1996 Aug; 15(8):688-93. PubMed ID: 8894583 [Abstract] [Full Text] [Related]